We have generated an IgG1 murine monoclonal anti-idiotype antibody (Ab2) designated 3H1, which mimics a specific epitope on the carcinoembryonic antigen (CEA). Patients with CEA positive tumors are immunologically "tolerant" to CEA. We used 3H1 as a surrogate for CEA for vaccine therapy of 12 patients with advanced colorectal cancer. Each of the patients received a minimum of four intracutaneous injections of aluminum hydroxide precipitated 3H1 at either 1, 2, or 4 mg dosage per injection. 9 of 12 patients demonstrated anti-anti-idiotypic (Ab3) response to 3H1. All nine patients generated specific anti-CEA antibody demonstrated by reactivity with radiolabeled purified CEA; some cases were confirmed by immunoprecipitation of purified CEA. We also demonstrated Ab3 stained both autologous and allogeneic colonic tumors. 7 of 12 patients demonstrated idiotype specific T cell proliferative responses and four also showed T cell proliferation to CEA. Toxicity was limited to local reaction with mild fever and chills. All 12 patients eventually progressed after finishing 4-13 dosages. This is the first report demonstrating that a vaccine therapy is capable of breaking "immune tolerance" to CEA in patients with CEA positive tumors. Future studies will focus on treating patients with minimal residual disease. (J. Clin. Invest. 1995. 96:334-342 
Introduction
Carcinoembryonic antigen (CEA)' is an 18-kD glycoprotein tumor-associated antigen present on entodermally derived neoplasms of the gastrointestinal tract as well as other adenocarcinomas ( 1) . CEA is also found in the digestive organs of the human fetus and, thus the name, CEA was derived. Circulating CEA can be detected in the great majority of patients with CEA positive tumors. Specific monoclonal antibodies have been raised against CEA (2-4) and some have been radiolabeled for diagnostic and clinical studies (5) . As with most tumorassociated antigens which are seen as self-antigens by the immune system, cancer patients are immunologically "tolerant" to CEA, likely related to its oncofetal origin. However, a limited number of reports from the 1970's suggested that some patients with CEA positive tumors may have minimal humoral and cellular immunity to CEA (6) (7) (8) (9) (10) ; these results are controversial.
The network hypothesis of Lindemann and Jerne (11, 12) offers an elegant approach to transform epitope structures into idiotypic determinants expressed on the surface of antibodies. According to the network concept, immunization with a given tumor-associated antigen will generate production of antibodies against this tumor-associated antigen, termed Abl; this Abi is then used to generate a series of anti-idiotype antibodies against the Abl, termed Ab2. Some of these Ab2 molecules can effectively mimic the three-dimensional structure of the tumor-associated antigen identified by the Abl. These particular anti-idiotypes called Ab2U fit into the paratopes of Abl, and express the internal image of the tumor-associated antigen. The Ab2,/ can induce specific immune responses similar to those induced by the original tumor-associated antigen and can, therefore, be used as surrogate tumor-associated antigens. Immunization with Ab2p can lead to the generation of anti-anti-idiotype antibodies (Ab3) that recognize the corresponding original tumor-associated antigen identified by Abl. Because of this AbI-like reactivity, the Ab3 is also called Ab ' to indicate that it might differ in its other idiotopes from Abl.
For several reasons, we consider CEA an excellent tumorassociated antigen for active immunotherapy with anti-idiotype antibody. First of all, CEA is typically present at high levels on the tumor cell surface. CEA is one of the most well-characterized antigens, its gene sequence is known and its three dimensional structures have been identified (13) . CEA is a member of the immunoglobulin supergene family (14) located on chromosome 19 which is thought to be involved in cell-cell interactions. Since CEA is considered an adhesion molecule (15, 16) , it might play an important role in the metastatic process by mediating attachment of tumor cells to normal cells. Thus, active immunotherapy targeted to CEA might be particularly beneficial in preventing metastasis.
Highly purified CEA is available from several sources and it can be used conveniently in serologic assays. Inasmuch as some of the epitopes on CEA are shared by normal tissues, immunization with intact CEA molecule might trigger potentially harmful autoimmune reactions. Whereas an Ab2P generated against an anti-CEA monoclonal antibody that recognizes a CEA-specific epitope, would be theoretically safer and more effective. Furthermore, Ab2fl expressed in a different molecular environment have been shown to overcome the immunosuppression in the host by stimulating "silent clones," and/or allowing (19) (20) (21) (22) (23) (24) (25) (26) (27) . We have generated and characterized an anti-idiotype murine monoclonal antibody to a murine monoclonal antibody designated 8019 that identifies a specific epitope on CEA (28) . This is a highly restricted CEA epitope that is not found on normal adult tissues and hematopoietic cells including granulocytes. The IgGl anti-idiotype antibody generated to 8019 was shown to be an internal image by generating anti-anti-idiotypic (Ab3) responses in mice, rabbits (29) , and monkeys (30) which recognized CEA. This anti-idiotype antibody was used to treat the patients reported in this clinical trial.
Methods
Selection of patients. All of the patients had CEA positive advanced colorectal carcinoma and failed standard therapies (Table I) . Baseline studies included complete physical examination, chest radiography, computer axial tomography examination of the abdomen, serum CEA level, routine blood counts, and chemistries. All of the patients had been off prior therapy for at least four weeks and staging was repeated at the conclusion of therapy.
Treatment schedule. The patients were treated intracutaneously with either 1, 2, or 4 mg of aluminum hydroxide precipitated anti-idiotype antibody every other week for four injections. If the patients were stable at the end of the four injections, they were then continued with injections on a monthly basis and evaluated every 3 mo. Patients were removed from study if they demonstrated growth of their tumor.
Generation of anti-idiotype antibody for the clinical trial. Murine monoclonal antibody 8019 was used to immunize syngeneic BALB/c mice for the production of anti-idiotype antibody. Immunization of BALB/c mice, hybridoma fusion and cloning, selection of anti-idiotype (Ab2), and production of ascites in bulk quantities in mice were done as previously described (31, 32 The Alu-Gel precipitated antibody was stored at 40C until use. These procedures were performed aseptically in a laminar flow hood and the final product was sterile and clearly labeled as anti-idiotype 3H1 AluGel and aliquoted into pyrogen-free, sterile glass vials.
The final product was tested for sterility, pyrogenicity and general safety in guinea pigs before use. An Investigational New Drug Application was approved through the United States Food and Drug Administration (BB-IND 5055).
Assays for humoral immunity. The development of humoral immunity induced by immunization with Alu-Gel-precipitated Ab2 was assessed by testing sera obtained from patients at different time points. The sera was initially tested for total human anti-murine-antibody responses including anti-iso/allo/and anti-anti-idiotype antibodies by sandwich radioimmunoassay (33) . Briefly, microtiter plates were coated with 3H1
and incubated with different dilutions of patients' sera. After washing, the antigen-antibody reaction was tagged using "2I-labeled anti-Id 3H1 in a homogeneous sandwich radioimmunoassay. Since 3H1 is injected as intact IgGl, patients are expected to mount human anti-mouse antibody responses.
Specific Ab3 response to Ab2. Sera from immunized patients with positive human anti-mouse antibody responses were tested for the presence of anti-anti-idiotypic antibodies. Sera were pre-incubated with normal murine immunoglobulin to block human antibodies against isotypic and allotypic determinants and then checked for the presence of antianti-idiotype (Ab3) by reaction with the immunizing anti-idiotype (3H1) coated onto microtiter plates. Unrelated Ab2 was used as control. After washing, the antigen-antibody reaction was tagged using '25I-labeled anti-idiotype reagent in a homogeneous sandwich radioimmunoassay as above. Pretreatment, non-immune sera and sera from normal donors were used as controls in these assays.
Inhibition of the binding between Abl and Ab2 by patients' Ab3
Immune Response to CEA in Patients Treated with an Anti-ldiotype Vaccineantibodies by radioimmunoassay. Pre-immune and hyperimmune patient sera samples were treated with unrelated murine immunoglobulins to remove anti-idiotypic and allotypic reactivities. Serial dilution's of sera were then tested for inhibition in the Abl-Ab2 binding assay. All assays were performed in triplicate. For direct binding inhibition assay between AbI and Ab2, purified Ab2 3H1 was used to coat plates (500 ng/well) and the binding of radiolabeled 8019 (Abl) to Ab2 was tested for inhibition in the presence of different patients' hyperimmune Ab3 sera and Abl. This demonstrated whether Ab3 in patients' sera shared idiotopes with 8019 (Abl). Also, this inhibition assay between Abl-Ab2 binding by Ab3 sera indicated whether Ab3 is a true anti-anti-idiotype. Detection of anti-CEA antibodies in patients immunized with Ab2 3HI. This assay was conducted to determine whether some of the Ab3 induced in patients by monoclonal murine Ab2 were of the AbI type and will bind to CEA. Purified CEA was radioiodinated with 1125 by the Chloramine T method. Radiolabeled CEA (1 X 106 cpm) was reacted with 0.5 ml of patient's serum pre-adsorbed on protein G-Sepharose beads. After reactions, the beads were washed and counted in a gamma-ray spectrophotometer. Pre-immune sera, phosphate-buffered saline-bovine serum albumin as well as Ab3 sera obtained from a patient treated with an unrelated murine monoclonal antibody for T cell lymphoma were used as controls in these assays.
Purified CEA. Purified CEA was obtained commercially from Rou- gier Biotech, Montreal, Canada (cat. No. 70015). CEA was isolated from human liver metastasis of colonic tumors by perchloric acid extraction and purified twice by ion-exchange chromatography followed by gel filtration and several steps of HPLC chromatography. The CEA is 100% pure, produced a single band at 18 kD by high power liquid chromatography and SDS-PAGE and was immunoprecipitated as a single band by horse as well as rabbit anti-CEA antibody. The CEA preparation was resolved into two closely migrating bands at 18 and 20 kD by Western blot analysis using murine monoclonal anti-CEA antibody. We The reactivities of monoclonal Abl and purified Ab3 at 10 Jig/ml solution were compared on surgical specimens of colonic adenocarcinomas by a very sensitive staining method (biotin-Streptavidin reagents; Vector, Burlingame, CA) as described in detail elsewhere (27) . All sections were counterstained with Meyer's hematoxylin. Pertinent specificity tests were performed, including block of the endogenous peroxidase, omission of the first layer, or substitution of nonimmune homologous serum for the specific antiserum and P3-653 myeloma culture supernatant as the control. Assay for T cell proliferative response. Peripheral blood mononuclear cells were isolated by standard Ficoll-Hypaque density gradient centrifugation method and S x 105 cells per well were incubated with different concentrations of 3HI-Alu-Gel and control 4DC6-Alu-Gel (10 ng to 2 jig) in RPMI medium with 5% heat-inactivated fetal calf serum and penicillin and streptomycin. The nonspecific mitogen phytohemagglutinin-P was used as a positive control at 2 and 1 jg per well. Peripheral blood mononuclear cells isolated from some selected patients were also incubated with different concentrations of purified CEA (10-250 ng) as per protocol above.
Assay for circulating CEA in serum. CEA was quantified in heatextracted serum. For this, lml of 0.2 m sodium acetate buffer, pH 5.0, was added to 0.5 ml of serum, vortex-mixed, incubated for 15 min at 90TC, and centrifuged ( 1,200 g, 10 min). The supernatants were assayed the same day or stored frozen at -20°C until assay. 100 ml of supernatant was then assayed by the enzyme immunoassay for CEA as described (35) .
Results
Humoral responses to anti-idiotype. The development of humoral immunity induced by immunization with Alu-Gel-precipitated Ab2, 3H1 was assessed by testing sera obtained from patients before therapy and after each treatment with the vaccine. Hyperimmune sera (after the fourth injection of 3H1) from nine of twelve patients showed significant levels of total human anti-mouse antibody responses including anti-iso/allo/ and anti-anti-idiotypic antibodies against immunizing Ab2, 3H1, as determined by homogeneous sandwich radioimmunoassay (data not shown). Next the sera from these immunized patients were checked for their ability to inhibit the binding of '25I-labeled Abl, 8019 to Ab2 3H1 on the plate by radioimmunoassay or vice versa (inhibition of radiolabeled Ab2 binding to AbI on the plate). These reactions were done in the presence of excess normal murine immunoglobulin to block human antibodies against isotypic and allotypic determinants. Fig. 1 (8019) binding to Ab2 (3H1) on the plate by patients' Ab3 sera by radioimmunoassay. Purified 3H1 was used to coat the plate (500 ng/well) and the binding of radiolabeled 8019 (-90,000 cpm) to 3H1 was tested for inhibition in the presence of various dilutions of Ab3 sera obtained from patients after the fourth immunization. sera obtained from patients after the fourth treatment were tested for the presence of antibody binding to radiolabeled purified CEA. We routinely used post fourth immunization because this was the number of injections all 12 patients received. For patients who received more than four injections, immune responses remained comparable or continued to increase in titer. A pure preparation of CEA was used to reduce the risk of obtaining false positive results due to nonspecific binding. As shown in Fig. 2 , immunization with 3H1 induced antibodies that bound to radiolabeled CEA. Nine of twelve patients developed anti-CEA antibodies measurable by this assay. Patients 4, 8, and 10 were anergic for human anti-mouse antibody response and did not produce antibodies against CEA, while patients 1, 2, 3, 5, and 12 showed high binding, and patients 6, 7, 9, and 11 showed binding greater than the background count obtained with PBS-BSA (Sample 13) or pre-immune sera (data not shown). Sample 14 was the AbI 8019 antibody used as a positive anti-CEA (8019) control.
Immuneflow cytometry analysis with Abl andpatient's Ab3. To determine the reactivity with cell-surface CEA, cultured CEA positive human colon cancer LS174T cells were tested by immune flow cytometry. As shown in Fig. 3 , crude sera from a representative 3Hl-immunized patient bound to LS174 T cells (A) similar to the binding pattern obtained with 8019 (B) and did not bind to human B cell lymphoma cells which do not express CEA (Fig. 3 C) (Fig. 4) (29) . To confirm that the Ab3 induced by 3H1 was specific for the CEA molecule, the iodinated purified CEA preparation was immunoprecipitated by purified Ab3 preparations obtained from two patients as well as Abl and analyzed by SDS-PAGE. The results in Fig. 5 indicate that both patient's Ab3 (lanes 2 and 3) precipitated the same 18 kD CEA band as that of murine Abl 8019 (lane 1). There was no cross-reactivity (lane 4) when the iodinated CEA was reacted with purified Ab3 obtained from a patient treated with an unrelated Ab2 (4DC6).. When iodinated CEA, pretreated with either of the two positive patients' Ab3 preparations, was reacted with 8019, there was no significant immunoprecipitation suggesting that the iodinated preparation was depleted of CEA (data not shown).
Immunoreactivity of Abi and patients' Ab3 on colonic tumor sections and nonnal tissues. We compared the reactivities of Abl (8019) with that of patients' purified Ab3 by a sensitive immunoperoxidase assay on autologous and allogeneic colon tumor specimens surgically removed from patients. The pattern of reactivity of patient Ab3 on autologous malignant colon tissues was identical to that obtained with allogeneic tumor specimens (Fig. 6, A and B, respectively) . AbI 8019 showed identical staining patterns (Fig. 6 C) , whereas there was no reactivity with control Ab3 obtained from a patient treated with an unrelated Ab2 (4DC6) (Fig. 6 D) . Reactions with Abl or purified Ab3 (Fig. 6, A-C ferentiated areas. There was no reactivity of Abl and purified Ab3 on normal tissues from colon (Fig. 6, E and F) , cecum, duodenum, stomach striated muscle or smooth muscle.
Cellular immune responses to anti-idiotype. Cellular immune responses were measured by the proliferation of peripheral blood mononuclear cells incubated with Alu-Gel precipitated anti-idiotype antibody 3H1 and Alu-Gel precipitated isotype matched control anti-idiotype antibody 4DC6. Positive proliferative responses were seen in seven of twelve patients. 104 All seven of these patients developed an Ab3 antibody response 10~ (Table I ). Representative data from two patients (1 and 12) are shown in Fig. 7, A and B. Pre-immune cells had no proliferative response to the anti-idiotype antibody while hyperimmune cells had a significant response. Four of the seven responding patients (two treated with a 2-mg dose and two with a 4-mg dose) also showed T cell proliferation in the presence of purified CEA suggesting antigen specific T cell response. There was also a response to the isotype matched 4DC6 Alu-Gel-precipitated anti-idiotype antibody; this response was significantly less than that of the 3H1 response, likely representing a response to the non-idiotype components of the murine immunoglobulin molecule. The difference in the response to 3H1-Alu-Gel compared with control 4DC6-Alu-Gel was significant (P < 0.003) as was the response to CEA compared to BSA (P < 0.005). There was no response to Alu-Gel itself (data not shown). Flow cytometric analysis of the cultures demonstrated that > 90% of the proliferating cells were CD4 positive T lymphocytes. The three patients who were anergic for human anti-mouse antibody response also did not demonstrate any T cell proliferative response. Of the five nonresponders, three were treated with 1 mg, one with 2 mg and one with 4 mg dosage of 3H1-Alu-Gel.
Toxicity and clinical response. Toxicity was minimal with only local reactions at the injection site with mild erythema and induration and mild fever and chills relieved by acetaminophen. The anti-idiotypic treatment did not have any deleterious effect on hematopoietic cells, renal, or hepatic function.
All 12 patients eventually developed progressive disease (Table   I ). (36) . Seven patients demonstrated idiotype specific T cell proliferative responses of primarily CD4 T cells. Four of them also demonstrated CEA-specific T cell proliferation in vitro. We will also study these patients' sera for in vitro killing of cultured tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and complement mediated cytotoxicity (CMC) assays. We do not have fresh or frozen autologous tumor tissues from these patients to test for in vitro cytotoxic T cell (CTL) induction, but will use HLA-Class 1 matched cultured colon tumor cell lines as targets.
To our knowledge, this is the first report in the literature describing the generation of specific and reproducible immunity to CEA. Whether this Ab3 and/or cellular immunity can mediate a potential anti-tumor effect remains to be determined. All of the patients in this study had prior chemotherapy and advanced disease; tumor regression was not noted. Future studies will focus on adjuvant trials where the goal will be elimination of minimal residual disease.
Another approach to generate active immunity to CEA has been the development of a recombinant vaccinia virus expressing the human CEA gene (37, 38) . This was made possible by the cloning of the CEA gene (39 (50) . Subsequent clinical trials using polyclonal non-CEA goat anti-idiotype (Ab2) vaccines for colorectal cancer (51) , and monoclonal anti-idiotypes for malignant melanoma (52, 53) have demonstrated that anti-idiotype vaccine therapy leads to active immune responses. In a recent study, idiotypespecific immune responses were induced in patients with B cell lymphoma against the immunoglobulin idiotype expressed by their tumors (54) . This latter study differed from ours in that the idiotype immunogen was derived from the patients' tumors, coupled to keyhole limpet hemocyanin and mixed with a potent adjuvant. Therefore, while we used a single anti-idiotype antibody as an antigen surrogate to treat all of our patients, these investigators generated an individualized vaccine for each of their patients.
In summary, we have demonstrated specific active immunity to CEA in patients with advanced colorectal cancer treated with an anti-idiotype antibody that "mimics" CEA. In this Phase lb clinical trial, we could only accrue patients who failed conventional therapy. All of them had widespread advanced disease. The main purpose of this clinical trial was not to assess tumor response, but to determine the host's immunological response to the vaccine therapy. Some primary questions have been resolved. This anti-idiotype antibody can evoke an Ab3 as well as cellular immune response in patients, and any Ab3 so derived, behaves as an Abi-like antibody (AbI ' ). The intensity of the Ab3 response appeared to correlate positively with anti-CEA antibody (Abl') and T cell proliferative responses. Immune responses appeared independent of the level of circulating CEA. While there are too few patients to compare the 1 mg, 2 and 4 mg doses; it is clear that patients were able to generate immunity at each of these doses. At the completion of this study we will statistically compare the different dose levels. Toxicity was restricted to local cutaneous reactions lasting 24-48 h with mild fever and chills and was relieved by acetaminophen.
Collectively, the immune responses in patients treated with an idiotype vaccine, which induced humoral and cellular responses against an otherwise non-immunogenic tumor antigen, justify follow-up clinical studies in patients with minimal tumor burden, as well as basic immunobiological studies to understand the mechanisms of the T cell response at the clonal level. Such studies may lead to the development of second generation idiotype vaccines consisting of cytokine-antibody fusion proteins (55) and of idiotype derived peptide vaccines (56) .
